We assessed the long-term safety, effectiveness and quality of a fixed-dose combination of nevirapine, stavudine and lamivudine (triomune). HIV-1-infected adults initially enrolled in a one-year, open-label, single-arm, multicentre trial in Cameroon were followed for 2 years. Our results support the safety and effectiveness of the triomune combination for first-line treatment of HIV infection. Virological effectiveness appeared to wane somewhat during the second year of treatment, however, and plasma nevirapine concentrations were relatively high.
aIRD, UMR 145 (IRD/University of Montpellier 1), Montpellier, France
bCentral Hospital, Yaoundé, Cameroon
cProjet PRESICA, Military Hospital, Yaoundé, Cameroon
dMédecins Sans Frontières, Geneva, Switzerland
eLaboratoire de Toxicologie et de Dosage de Médicaments, Centre Hospitalier Universitaire Bichat Claude Bernard, Paris, France.
Received 2 May, 2006
Revised 24 May, 2006
Accepted 4 June, 2006
Correspondence to Christian Laurent, Institut de Recherche pour le Développement (UMR 145), 911 Avenue Agropolis, BP 64501, 34394 Montpellier cedex 5, France. E-mail: christian.Laurent@mpl.ird.fr